Evidence map›Paper›PMID 33422679›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2021

Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For.

Michele Carbone, John Lednicky, Shu-Yuan Xiao, Mario Venditti, Enrico Bucci

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. AYUSH- 64: A potential therapeutic agent in COVID-19.Journal of Ayurveda and integrative medicine
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Michele CarboneThoracic Oncology, University of Hawaii Cancer Center, Honolulu, Hawaii; Department of Pathology, John A. Burns School of Medicine, Hawaii, Honolulu, Hawaii. Electronic address: mcarbone@cc.hawaii.edu.
John LednickyDepartment of Environmental and Global Health, College of Public Health and Health Professions, Emerging Pathogens Institute, University of Florida, Gainesville, Florida.
Shu-Yuan XiaoDepartment of Pathology, University of Chicago Medicine, Chicago, llinois.
Mario VendittiDepartment of Public Health and Infectious Diseases, Universita` La Sapienza, Roma, Italy.
Enrico BucciSbarro Institute for Cancer Research and Molecular Medicine, College for Science and technology, Temple University, Philadelphia, Pennsylvania; Department of Biology, College for Science and Technology, Temple University, Philadelphia, Pennsylvania.
Sapienza University of Rome · ITTemple College · USUniversity of Chicago · USUniversity of Florida · USUniversity of Hawaiʻi at Mānoa · US

Funding

Mechanisms of BAP1 activity in human cancer developmentR01CA237235 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE, YANG, HAINING · 2020 to 2024
$2.1M
Influence of germline mutations on susceptibility to environmental carcinogensR01ES030948 · NIEHS · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE, GRZYMSKI, JOSEPH J · 2019 to 2021
$1.9M
Germline BAP1 Mutations and Malignant Mesothelioma: Mechanisms and Early DetectionR01CA198138 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE · 2015 to 2019
$1.7M
NCI NIH HHS R01 CA198138NCI NIH HHS R01 CA237235NIEHS NIH HHS R01 ES030948
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads mainly by means of aerosols (microdroplets) in enclosed environments, especially those in which temperature and humidity are regulated by means of air-conditioning. About 30% of individuals infected with SARS-CoV-2 develop coronavirus disease 2019 (COVID-19) disease. Among them, approximately 25% require hospitalization. In medicine, cases are identified as those who become ill. During this pandemic, cases have been identified as those with a positive SARS-CoV-2 polymerase chain reaction test, including approximately 70% who were asymptomatic-this has caused unnecessary anxiety. Individuals more than 65 years old, those affected by obesity, diabetes, asthma, or are immune-depressed owing to cancer and other conditions, are at a higher risk of hospitalization and of dying of COVID-19. Healthy individuals younger than 40 years very rarely die of COVID-19. Estimates of the COVID-19 mortality rate vary because the definition of COVID-19-related deaths varies. Belgium has the highest death rate at 154.9 per 100,000 persons, because it includes anyone who died with symptoms compatible with COVID-19, even those never tested for SARS-CoV-2. The United States includes all patients who died with a positive test, whether they died because of, or with, SARS-CoV-2. Countries that include only patients in which COVID-19 was the main cause of death, rather than a cofactor, have lower death rates. Numerous therapies are being developed, and rapid improvements are anticipated. Because of disinformation, only approximately 50% of the U.S. population plans to receive a COVID-19 vaccine. By sharing accurate information, physicians, health professionals, and scientists play a key role in addressing myths and anxiety, help public health officials enact measures to decrease infections, and provide the best care for those who become sick. In this article, we discuss these issues.

Indexed as

Communicable DiseasesCoronavirusCOVID-19Lung NeoplasmsAgedCOVID-19 VaccinesHumansSARS-CoV-2United StatesCOVID-19 VaccinesCoronavirusCOVID-19COVID-19 transmissionpandemicSARS-CoV-2

Identifiers

PMID33422679
PMCPMC7832772
OpenAlexW3118644762

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.